Strong Domestic Operations:
Jenburkt Pharma Ltd., engaged in manufacturing and marketing of speciality and high
quality pharmaceutical formulations and healthcare products, has a strong committed
sales force team spread across India. Jenburkt promotes all its 85 brands ethically
across 75,000 doctors and 50,000 chemists regularly. Backing the strong sales force,
the company has more than 1,000 stockists and 25 super-stockists. Jenburkt also
caters to large Government and Semi-Government Institutions, Missionary Hospitals,
Public Sector Enterprises, etc.
Strengthening the Company’s Brands:
There is a growing trend of competition from regional companies who operate either
in a few districts or in a few states in India. This is apart from the competition
from large organizations operating in India. In order to tackle competition, during
the previous year, the company focussed on strengthening its brands in their respective
segments. Additionally, neuropathy detection camps and bone densitometry camps were
carried out in various parts of the country for detection of neuropathy and osteoporosis.
The strategy of the company is to focus on long term therapies in acute and chronic
ailments by moving up the value chain continuously. As a result, a few of the company’s
brands are the preferred choice in certain segments. The company has some strong
brands including CARTI SAFE FORTE (Anti Arthritic), POWERGESIC Tablets (Anti Inflammatory
Analgesic). It ranks among the top five in these segments.
Quality Products’ Portfolio:
Jenburkt has a strong portfolio of quality products that include prescription and
over-the-counter drugs. The company’s prescription medicines span across various
therapeutic areas such as anti-arthritic, anti-malarials, anti-osteoporotic, antibiotics,
anti-diabetics, anti-inflammatory drugs and more.
Strong Manufacturing Facilities:
Jenburkt has strong manufacturing facilities to cater to both the domestic and international
markets. The company has a state-of-the-art manufacturing plant at Sihor-Gujarat
in India. The plant is modern and well-equipped with spacious operational areas
having adequate capacities for manufacturing world-class pharmaceutical and healthcare
products. The company’s plant is approved as per W.H.O. (World Health Organization)
guidelines and has approvals from various countries. Furthering the development
of formulations, Jenburkt has a Research & Development unit duly approved by the
Ministry of Science & Technology, Government of India. Jenburkt also manufactures
high quality formulations backed by strong Research & Development which adheres
to regulations and is marketed by its global marketing team. Jenburkt's strategy
is to focus on creating a new category in the Indian and the International pharmaceutical
Strong R&D Activities:
Through Research & Development, the company is in the continuous process of improving
on its product portfolio. Recently, the company undertook commercial scale manufacturing
of Frendacid, an antacid and anti-flatulence drug for the export market. The company
also continues to work towards formulating new and existing molecules for the domestic
and international markets for efficient and cost saving drug delivery systems.
Growing Export Market:
Currently, Jenburkt's products are being exported to 15 countries globally with
a clear focus to expand on a yearly basis. The company is also scouting for a capable
partner to market its pharmaceutical products across the globe in order to increase
its export sales which presently constitutes a modest proportion of total sales.
Also Jenburkt is open to partnering with foreign pharmaceutical firms to market
their pharmaceutical products in India.
Resolved export oriented issues:
The company’s export sales presently contribute 14% of the total sales. Jenburkt
faced some challenges with some of its export markets, particularly Sri Lanka, which
contributes to around 6% of sales where a leading distributor in the country was
facing financial instability and top management attrition. To overcome this issue,
Jenburkt appointed a new distributor which impacted 4 months of sales thereby affecting
its lucrative export business margins.
Apart from Sri Lanka, the company faced challenges in Benin (Africa) too where due
to political uncertainty, distributors were not accepting orders. However, these
issues have been resolved and exports have resumed.